FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy with Direct Brain Administration for AADC Deficiency
Key Insights
The FDA granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq (search)) for AADC deficiency (search), marking the first gene therapy approved in the U.S. for direct brain administration.
Kebilidi, a gene replacement therapy, is indicated for both children and adults with AADC deficiency (search), addressing the full spectrum of disease severity by restoring dopamine synthesis.
Clinical trials demonstrated significant gross motor function improvement in 8 of 12 treated pediatric patients, a milestone not typically observed in untreated patients with severe AADC deficiency (search).
The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq (search)), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This marks the first gene therapy approved in the U.S. that involves direct administration to the brain. The approval is a significant advancement for patients with this rare genetic disorder, which impairs motor function due to the inability to synthesize dopamine.
Kebilidi: A Gene Replacement Therapy
Kebilidi is a gene replacement therapy administered directly into the putamen of the brain via a stereotactic neurosurgical procedure. The treatment involves four infusions in a single surgical session, targeting a key structure involved in motor control. By delivering a functional gene, Kebilidi aims to restore dopamine synthesis in patients with AADC deficiency (search).
AADC deficiency (search) is a rare genetic disorder that prevents the synthesis of dopamine, a crucial neurotransmitter for motor function. Individuals with this deficiency often experience delays in motor skills such as head control, sitting, standing, and walking, as well as hypotonia (weak muscle tone) and developmental delays.
Clinical Trial Efficacy
The safety and efficacy of Kebilidi were demonstrated in an open-label, single-arm clinical study involving 13 pediatric patients. Results showed that the gene therapy led to de novo synthesis of dopamine, followed by progressive acquisition of motor development milestones. Specifically, gross motor function improvement was observed in 8 of 12 treated patients, a result not typically seen in untreated patients with severe AADC deficiency (search).
The approval was based on the safety and clinical efficacy findings from the ongoing global gene therapy clinical trial (PTC-AADC-GT-002). Continued long-term follow-up of treated patients will provide further confirmatory evidence.
Regulatory and Market Impact
With the approval, a rare disease priority review voucher was granted, which PTC Therapeutics plans to monetize. Barclays has maintained an Equal-Weight rating for PTC Therapeutics, raising the price target from $43 to $45.